Change in type-2 biomarkers and related cytokines with prednisolone in uncontrolled severe oral corticosteroid dependent asthmatics: an interventional open-label study

John Busby, Cécile Holweg, Akiko Chai, Peter Bradding, Fang Cai, Rekha Chaudhuri, Adel Mansur, James Lordan, John G. Matthews, Andrew Menzies-Gow, Rob Niven, Tracy Staton, Liam G Heaney, Medical Research Council UK Refractory Asthma Stratification Programme (RASP-UK)

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)
202 Downloads (Pure)

Abstract

Type-2 biomarkers and related cytokines (IL-5, IL-13), lung function and asthma symptoms were measured in 44 poorly-controlled severe oral corticosteroid (OCS)-dependent asthmatics for up to 88 days after a seven-day prednisolone boost (0.5mg/kg). High-dose OCS reduced median blood eosinophils (-60cells/µl; 95% CI: -140, -10), periostin (-8.4ng/ml; -11.6, -2.8), FeNO (-19.0ppb; -28.5, -4.0), IL-5 ( 0.17pg/ml; -0.28, -0.08) and IL-13 (-0.15pg/ml; -0.27, -0.03). There were small improvements in mean FEV1 (0.16L; 0.05, 0.27) and ACQ-7 score (0.3; 0.0, 0.7). Study measures returned to baseline one month post-intervention. Following rescue OCS, one month is sufficient before using type-2 biomarkers to guide long-term treatment.
Original languageEnglish
Pages (from-to)806-809
Number of pages4
JournalThorax
Volume74
Issue number8
Early online date02 Apr 2019
DOIs
Publication statusPublished - 15 Jul 2019

Bibliographical note

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Keywords

  • Asthma
  • Corticosteroid

Fingerprint Dive into the research topics of 'Change in type-2 biomarkers and related cytokines with prednisolone in uncontrolled severe oral corticosteroid dependent asthmatics: an interventional open-label study'. Together they form a unique fingerprint.

Cite this